A Cost-Utility Analysis of Endovascular Thrombectomy in a Real-World Setting

• Published in: Canadian journal of neurological sciences 2020-01, Vol.47 (1), p.50-60
• Main Authors: Koto, Prosper S, Hu, Sherry X, Virani, Karim, Simpkin, Wendy L, Christian, Christine A, Cao, Huiling, Shankar, Jai J S, Phillips, Stephen J
• Format: Article
• Language: English
• Subjects: Computed tomography; Cost analysis; Discount rates; Life expectancy; Patients; Sensitivity analysis; Stroke
• ISSN: 0317-1671
• DOI: 10.1017/cjn.2019.308

Objective:Endovascular thrombectomy (EVT) is efficacious for ischemic stroke caused by proximal intracranial large-vessel occlusion involving the anterior cerebral circulation. However, evidence of its cost-effectiveness, especially in a real-world setting, is limited. We assessed whether EVT ± tissue plasminogen activator (tPA) was cost-effective when compared with standard care ± tPA at our center.Method:We identified patients treated with EVT ± tPA after the Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing computed tomography to recanalization times trial from our prospective stroke registry from February 1, 2013 to January 31, 2017. Patients admitted before February 2013 and treated with standard care ± tPA constitute the controls. The sample size was 88. Cost-effectiveness was assessed using the net monetary benefit (NMB). Differences in average costs and quality-adjusted life years (QALYs) were estimated using the augmented inverse probability weighted estimator. We accounted for sampling and methodological uncertainty in sensitivity analyses.Results:Patients treated with EVT ± tPA had a net gain of 2.89 [95% confidence interval (CI): 0.93–4.99] QALYs at an additional cost of $22,200 (95% CI: −28,902–78,244) per patient compared with the standard care ± tPA group. The NMB was $122,300 (95% CI: −4777–253,133) with a 0.85 probability of being cost-effective. The expected savings to the healthcare system would amount to $321,334 per year.Conclusion:EVT ± tPA had higher costs and higher QALYs compared with the control, and is likely to be cost-effective at a willingness-to-pay threshold of $50,000 per QALY.